KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kronos Bio, Inc.(NasdaqGS:KRON) added to NASDAQ Biotechnology Index

12/20/2021 | 12:00am EDT

Kronos Bio, Inc. has been added to NASDAQ Biotechnology Index.


© S&P Capital IQ 2021
All news about KRONOS BIO, INC.
05/24Goldman Sachs Adjusts Price Target for Kronos Bio to $23 From $35, Reiterates Buy Ratin..
MT
05/23Piper Sanler Lowers Kronos Bio's Price Target to $13 From $30, Maintains Overweight Rat..
MT
05/20INSIDER BUY : Kronos Bio
MT
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/12Kronos Bio to Feature Entospletinib, Lanraplenib Investigational Inhibitors at European..
MT
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/04KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/04Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
GL
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -155 M - -
Net cash 2022 73,0 M - -
P/E ratio 2022 -1,18x
Yield 2022 -
Capitalization 191 M 191 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 96
Free-Float 85,5%
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,36 $
Average target price 22,25 $
Spread / Average Target 562%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-75.28%191
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232